Radionetics Oncology, a biotechnology company specializing in small molecule G protein coupled receptor (GPCR) targeted radiopharmaceuticals, has announced a strategic relationship with Eli Lilly and Company. This partnership aims to advance Radionetics’ proprietary GPCR-targeted small molecule radiopharmaceuticals for treating various solid tumors. The collaboration marks a significant step in the development of innovative cancer therapies.
As part of the agreement, Radionetics received a substantial $140 million upfront cash payment from Lilly. Additionally, Lilly secured the exclusive right to acquire Radionetics for $1 billion at the end of an exercise period. During this period, Radionetics will continue to develop its proprietary pipeline of therapeutic assets, focusing on small molecule radioligand therapeutics targeting GPCRs, leveraging its unique discovery platform and associated intellectual property.
Paul Grayson, CEO of Radionetics Oncology, expressed his enthusiasm about the partnership, highlighting Lilly’s global development capability, oncology expertise, and growing radiopharmaceutical experience following its acquisition of POINT Biopharma. This strategic alignment is expected to enhance the development and potential success of Radionetics’ innovative therapies.
Jacob Van Naarden, Executive Vice President and President of Lilly Oncology, emphasized Lilly's commitment to radiopharmaceutical therapies and the value of Radionetics’ novel GPCR targets and discovery capabilities. He noted that this relationship would further bolster Lilly’s efforts to bring groundbreaking treatments to cancer patients.
Lilly was also in the news last week for partnering with OpenAI to combat antimicrobial resistance, which we covered here.
Click here to read the original news story.